Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a...
Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
About this item
Full title
Author / Creator
Kaneko, Yutaro , Hatano, Ryo , Hirota, Naoto , Isambert, Nicolas , Trillet-Lenoir, Véronique , You, Benoit , Alexandre, Jérôme , Zalcman, Gérard , Valleix, Fanny , Podoll, Thomas , Umezawa, Yoshimi , Takao, Seiichi , Iwata, Satoshi , Hosono, Osamu , Taguchi, Tetsuo , Yamada, Taketo , Dang, Nam H. , Ohnuma, Kei , Angevin, Eric and Morimoto, Chikao
Publisher
England: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central
Subjects
More information
Scope and Contents
Contents
The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I data.
Box and Whisker plot analysis, Scatter plot analysis, Peason product moment correlation/Spearman's rank-differ...
Alternative Titles
Full title
Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
Authors, Artists and Contributors
Author / Creator
Hatano, Ryo
Hirota, Naoto
Isambert, Nicolas
Trillet-Lenoir, Véronique
You, Benoit
Alexandre, Jérôme
Zalcman, Gérard
Valleix, Fanny
Podoll, Thomas
Umezawa, Yoshimi
Takao, Seiichi
Iwata, Satoshi
Hosono, Osamu
Taguchi, Tetsuo
Yamada, Taketo
Dang, Nam H.
Ohnuma, Kei
Angevin, Eric
Morimoto, Chikao
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_869532e7d9924a45b065a8c40a83cd05
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_869532e7d9924a45b065a8c40a83cd05
Other Identifiers
ISSN
2050-7771
E-ISSN
2050-7771
DOI
10.1186/s40364-021-00273-0
